三诺生物
(300298)
| 流通市值：105.46亿 | | | 总市值：130.74亿 |
| 流通股本：4.55亿 | | | 总股本：5.64亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,013,580,318.64 | 4,058,786,045.41 | 3,035,326,703.91 | 2,007,341,216.22 |
| 营业收入 | 1,013,580,318.64 | 4,058,786,045.41 | 3,035,326,703.91 | 2,007,341,216.22 |
| 二、营业总成本 | 921,145,209.82 | 3,730,526,477.87 | 2,758,785,843.67 | 1,866,958,061.48 |
| 营业成本 | 499,413,679.89 | 1,864,682,259.15 | 1,425,352,835.02 | 979,851,100.84 |
| 税金及附加 | 9,526,471.37 | 40,610,098.6 | 27,796,416.37 | 18,323,901.96 |
| 销售费用 | 249,931,249.8 | 1,001,480,697.49 | 716,388,154.59 | 477,317,570.78 |
| 管理费用 | 65,828,654.51 | 418,257,904.09 | 315,272,708.5 | 204,432,862.27 |
| 研发费用 | 95,585,949.49 | 356,405,035.56 | 245,429,651.5 | 161,267,395.57 |
| 财务费用 | 859,204.76 | 49,090,482.98 | 28,546,077.69 | 25,765,230.06 |
| 其中:利息费用 | 13,003,522.58 | 66,284,974.73 | 52,621,781.31 | 38,142,103.54 |
| 其中:利息收入 | 5,433,877.12 | 17,927,995.17 | 11,460,888.45 | 8,047,338.21 |
| 加:投资收益 | 145,920.15 | 733,004.45 | 1,129,075.93 | 105,653.69 |
| 资产处置收益 | -2,961,669.08 | -6,004,816.23 | -2,870,477.2 | -3,064,620.48 |
| 资产减值损失(新) | -657,769.86 | -116,745,988.41 | -2,765,086.38 | -5,403,843.87 |
| 信用减值损失(新) | -5,321,404.29 | -13,403,548.76 | -8,766,559.08 | -3,877,359.57 |
| 其他收益 | 25,263,022.21 | 82,172,941.15 | 78,455,149.68 | 57,211,896.31 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 108,903,207.95 | 275,011,159.74 | 341,722,963.19 | 185,354,880.82 |
| 加:营业外收入 | 199,641.9 | 1,213,324.18 | 252,547.76 | 124,420.39 |
| 减:营业外支出 | 358,853.61 | 27,663,478.83 | 11,787,746.51 | 11,403,692.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 108,743,996.24 | 248,561,005.09 | 330,187,764.44 | 174,075,608.56 |
| 减:所得税费用 | 17,122,808.23 | 52,716,009.63 | 52,494,703.73 | 34,555,258.62 |
| 六、净利润 | 91,621,188.01 | 195,844,995.46 | 277,693,060.71 | 139,520,349.94 |
| 持续经营净利润 | 91,621,188.01 | 195,844,995.46 | 277,693,060.71 | 139,520,349.94 |
| 归属于母公司股东的净利润 | 80,937,582.74 | 284,397,911.89 | 318,029,312.81 | 175,368,479.46 |
| 少数股东损益 | 10,683,605.27 | -88,552,916.43 | -40,336,252.1 | -35,848,129.52 |
| (一)基本每股收益 | 0.15 | 0.51 | 0.57 | 0.31 |
| (二)稀释每股收益 | 0.15 | 0.51 | 0.57 | 0.31 |
| 八、其他综合收益 | -34,870,743.31 | 40,731,598.7 | 66,494,404.13 | 82,666,835.58 |
| 归属于母公司股东的其他综合收益 | -32,277,610.06 | 30,168,975.42 | 46,213,825.16 | 62,386,256.61 |
| 九、综合收益总额 | 56,750,444.7 | 236,576,594.16 | 344,187,464.84 | 222,187,185.52 |
| 归属于母公司股东的综合收益总额 | 48,659,972.68 | 314,566,887.31 | 364,243,137.97 | 237,754,736.07 |
| 归属于少数股东的综合收益总额 | 8,090,472.02 | -77,990,293.15 | -20,055,673.13 | -15,567,550.55 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-24 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |